Supplementary protection
LT - Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
EN - ANTIBODIES SPECIFIC FOR HUMAN CD22 AND THEIR THERAPEUTIC AND DIAGNOSTIC USES
SPC
| (11) |
Number of the document |
C 1504035 |
| (68) |
Number of the document |
1504035
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2017 043 |
| (22) |
Date of filing the application |
2017-12-21 |
| (41) |
Date of publication of the application |
2018-01-10 |
|
Date of publication of SPC |
2022-03-25 |
| (24) |
Date of coming into effect of SPC |
2023-05-03 |
Applicant
| (71) |
UCB Pharma, S.A.,
Allée de La Recherche 60, 1070 Brussels,
BE
|
Grantee
| (73) |
UCB Pharma, S.A.,
Allée de La Recherche 60, 1070 Brussels,
BE
|
Attorney or representative
| (74) |
Stanislava TELEIŠIENĖ,
UAB "Brainera", Taikos 235-17, LT-05213 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/17/1200/001, 2017-06-29
|
Calculated date of expiry of the SPC
| (94) |
2028-05-02 |
Name of the product protected by the basic patent
| (95) |
Inotuzumabas |
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2025-04-02 |
3 |
347.00
EUR
|
Next renewal fee
|
2026-05-03 |
